相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator-controlled phase 3 AMAGINE-2 trial
Luis Puig et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)
Maxime Dougados et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial
A. Blauvelt et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials
Kristian Reich et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Emilie Sbidian et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2020)
Psoriasis: Which therapy for which patient Psoriasis comorbidities and preferred systemic agents
Shivani B. Kaushik et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Psoriasis: Which therapy for which patient Focus on special populations and chronic infections
Shivani B. Kaushik et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies
Farzad Alinaghi et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study
Carle Paul et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: Results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study
Elizabeth G. Araujo et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2019)
Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study
Youssef A. Elnabawi et al.
CARDIOVASCULAR RESEARCH (2019)
Hyperglycemia Is Associated with Psoriatic Inflammation in Both Humans and Mice
Kyoko Ikumi et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2019)
Efficacy and safety of systemic treatments in psoriatic arthritis: a systematic review, meta-analysis and GRADE evaluation
C. Dressler et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2019)
Comparative efficacy and safety of targeted DMARDs for active psoriatic arthritis during induction therapy: A systematic review and network meta-analysis
Chenyang Lu et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2019)
Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial
Kristian Reich et al.
LANCET (2019)
Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response
Laura M. Sawyer et al.
PLOS ONE (2019)
Network meta-analyses of systemic treatments for psoriasis: a critical appraisal
A. G. Ellis et al.
BRITISH JOURNAL OF DERMATOLOGY (2019)
Impact of Secukinumab on Endothelial Dysfunction and Other Cardiovascular Disease Parameters in Psoriasis Patients over 52 Weeks
Esther von Stebut et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2019)
Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response
L. M. Sawyer et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2019)
RORγt inhibition selectively targets IL-17 producing iNKT and γδ-T cells enriched in Spondyloarthritis patients
Koen Venken et al.
NATURE COMMUNICATIONS (2019)
Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis
Jasvinder A. Singh et al.
ARTHRITIS & RHEUMATOLOGY (2019)
Safety of biologics in psoriasis
Masahiro Kamata et al.
JOURNAL OF DERMATOLOGY (2018)
Pathogenesis of psoriasis and development of treatment
Eisaku Ogawa et al.
JOURNAL OF DERMATOLOGY (2018)
Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis
P. Kawalec et al.
RHEUMATOLOGY INTERNATIONAL (2018)
Resident T Cells in Resolved Psoriasis Steer Tissue Responses that Stratify Clinical Outcome
Irene Gallais Serezal et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2018)
Influence of Axial Involvement on Clinical Characteristics of Psoriatic Arthritis: Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
Philip J. Mease et al.
JOURNAL OF RHEUMATOLOGY (2018)
Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR)
Bruce Strober et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions A Secondary Analysis of 2 Randomized Clinical Trials
Peter Foley et al.
JAMA DERMATOLOGY (2018)
Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study
Dominique Baeten et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials
Kenneth B. Gordon et al.
LANCET (2018)
Distinguishing rheumatoid arthritis from psoriatic arthritis
Joseph F. Merola et al.
RMD OPEN (2018)
Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies
K. B. Gordon et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J)
Hidehisa Saeki et al.
JOURNAL OF DERMATOLOGY (2017)
Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn's Disease: A Phase 2a Study
Bruce E. Sands et al.
GASTROENTEROLOGY (2017)
CD49a Expression Defines Tissue-Resident CD8+ T Cells Poised for Cytotoxic Function in Human Skin
Stanley Cheuk et al.
IMMUNITY (2017)
Inflammatory skin march in atopic dermatitis and psoriasis
Masutaka Furue et al.
INFLAMMATION RESEARCH (2017)
Efficacy and safety of ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis: Subgroup analysis of a placebo-controlled, phase 3 study (UNCOVER-1)
Shinichi Imafuku et al.
JOURNAL OF DERMATOLOGY (2017)
Dynamic Changes in Resident and Infiltrating Epidermal Dendritic Cells in Active and Resolved Psoriasis
Elisa Martini et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2017)
Systematic review and meta-analysis of the association between psoriasis and metabolic syndrome
Milton Jose Max Rodriguez-Zuniga et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Psoriasis and suicidality: A systematic review and meta-analysis
Sanminder Singh et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Psoriasis and comorbid diseases Epidemiology
Junko Takeshita et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-α inhibitors versus methotrexate
Jashin J. Wu et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3)
Andrew Blauvelt et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparatore-controlled VOYAGE 1 trial
Andrew Blauvelt et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3)
Andrew Blauvelt et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial
Peter Nash et al.
LANCET (2017)
Enthesitis: from pathophysiology to treatment
Georg Schett et al.
NATURE REVIEWS RHEUMATOLOGY (2017)
Psoriatic Arthritis
Christopher T. Ritchlin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn's Disease
Stephan R. Targan et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2016)
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
K. B. Gordon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease
B. G. Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Increased Prevalence of Coronary Artery Disease in Severe Psoriasis and Severe Atopic Dermatitis
Kasper Fjellhaugen Hjuler et al.
AMERICAN JOURNAL OF MEDICINE (2015)
The Psychological Burden of Skin Diseases: A Cross-Sectional Multicenter Study among Dermatological Out-Patients in 13 European Countries
Florence J. Dalgard et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2015)
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
Christopher E. M. Griffiths et al.
LANCET (2015)
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
Dominique Baeten et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
M. Lebwohl et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Increased number and frequency of group 3 innate lymphoid cells in nonlesional psoriatic skin
B. Dyring-Andersen et al.
BRITISH JOURNAL OF DERMATOLOGY (2014)
Body mass index, waist circumference and HOMA-IR correlate with the Psoriasis Area and Severity Index in patients with psoriasis receiving phototherapy
A. M. Tobin et al.
BRITISH JOURNAL OF DERMATOLOGY (2014)
Epidermal Th22 and Tc17 Cells Form a Localized Disease Memory in Clinically Healed Psoriasis
Stanley Cheuk et al.
JOURNAL OF IMMUNOLOGY (2014)
Characterization of Innate Lymphoid Cells in Human Skin and Blood Demonstrates Increase of NKp44+ILC3 in Psoriasis
Federica Villanova et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2014)
The Prevalence and Odds of Depressive Symptoms and Clinical Depression in Psoriasis Patients: A Systematic Review and Meta-Analysis
Emmilia A. Dowlatshahi et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2014)
Interleukin 17A: Toward a new understanding of psoriasis pathogenesis
Charles W. Lynde et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2014)
Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence
Rosa Parisi et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2013)
Psoriasis and Major Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis of Observational Studies
Ehrin J. Armstrong et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2013)
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial
Wolfgang Hueber et al.
GUT (2012)
Diagnosis and classification in spondyloarthritis: identifying a chameleon
Astrid van Tubergen et al.
NATURE REVIEWS RHEUMATOLOGY (2012)
The 'psoriatic march': a concept of how severe psoriasis may drive cardiovascular comorbidity
Wolf-Henning Boehncke et al.
EXPERIMENTAL DERMATOLOGY (2011)
Anti-tumor necrosis factor alpha treatment with adalimumab improves significantly endothelial function and decreases inflammatory process in patients with chronic psoriasis
Georgia Avgerinou et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2011)
Neutralisation of Dkk-1 protects from systemic bone loss during inflammation and reduces sclerostin expression
Gisela Ruiz Heiland et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Psoriasis associated with ulcerative colitis and Crohn's disease
A. D. Cohen et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2009)
Impact of Body Mass Index and Obesity on Clinical Response to Systemic Treatment for Psoriasis
Luigi Naldi et al.
DERMATOLOGY (2008)
Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review
W. Sterry et al.
BRITISH JOURNAL OF DERMATOLOGY (2007)
Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: Results from an Italian case-control study
L Naldi et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2005)
分享论文
